Sporothrix brasiliensis has emerged as an important cause of sporotrichosis, particularly associated with feline and zoonotic cases. Owing to the paucity of data on antifungal activity against this species, the present study aimed to evaluate the in vitro susceptibility of clinical isolates of S. brasiliensis in the mycelial and yeast phases to itraconazole (ITZ), terbinafine (TRB), and amphotericin B (AMB). Thirty-five isolates from an outbreak of feline sporotrichosis in Southern Brazil were used. All of them were assessed in the yeast and filamentous phases using the broth microdilution technique in accordance with the respective reference protocols M27-A3 and M38-A2 of the Clinical and Laboratory Standards Institute (CLSI). In our study, TRB was the most active antifungal against both the filamentous and yeast phases, showing GM of the MIC of 0.343 μg/ml and 0.127 μg/ml, respectively. In the yeast phase, the GM of the MIC for TRB was significantly lower than that for both ITZ (P = .009) and AMB (P < .001). However, in the filamentous phase, the GM of the MIC for TRB was significantly lower than that of AMB (P < .001), but not different from that of ITZ (P = .091). AMB was the antifungal with the highest GM of the MIC for both phases (1.486 μg/ml for the filamentous phase and 0.660 μg/ml for the yeast). Our results may contribute to a better understanding of antifungal susceptibility profiles of clinical isolates of S. brasiliensis in the mycelial and yeast phases in further studies.
Introduction
Sporotrichosis is the main subcutaneous mycosis in Brazil caused by members of a group of dimorphic fungus named as Sporothrix complex. [1] [2] [3] [4] The disease is acquired by traumatic inoculation of the microorganism and, in some states such as Rio de Janeiro, São Paulo, and Rio Grande do Sul, its epidemiology is changing. A modification has been occurred in its sapronotic characteristic, with an increase in the transmission by animals and especially domestic cats, highlighting the zoonotic characteristic. 1, [5] [6] [7] [8] In the last decades, molecular studies have provided significant evidence that infected domestic cats are the primary disseminator of sporotrichosis, as well as the main source of infections by the species Sporothrix brasiliensis in humans and others animals (cats, rats, dog, and armadillo). 4 S. brasiliensis has been considered the most sensitive species to the majority of available antifungal agents in vitro, 7 although this is the most virulent species of the Sporothrix complex and is responsible for atypical clinical manifestations of the disease in humans. [8] [9] [10] [11] Recently, our group described an outbreak of feline sporotrichosis in Rio Grande, RS, Brazil, and molecular characterization of isolates revealed that S. brasiliensis was the etiologic agent of all cases in which the pathogen was identified to the species level. 9 The standard method of performing in vitro antifungal susceptibility tests uses the mycelial phase of the Sporothrix complex. 12 However, the pathogenic agent is the yeast, and studies have reported differences in the results of antifungal susceptibility between the yeast and mycelial forms of Sporothrix spp. [13] [14] [15] Isolates from the extreme south of Rio Grande do Sul are the focus of this study because of the significant number of sporotrichosis cases in comparison with adjacent areas, with the epicenter of this disease in the city of Rio Grande. 3, 9, 16, 17 Considering the importance of the species S. brasiliensis in zoonotic cases of sporotrichosis and the lack of specific data on the in vitro susceptibility of this species, 7, 15, 18, 19 the aim of this study was to evaluate and compare the antifungal susceptibilities of clinical isolates of S. brasiliensis in both the mycelial and yeast phases from the outbreak that occurred in southern Rio Grande do Sul, Brazil.
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Materials and methods
Fungal isolates
The 35 clinical isolates of S. brasiliensis tested in this study were obtained from cats with sporotrichosis ( Fig. 1 
Antifungal drugs
Three antifungals were used in the susceptibility test: amphotericin B deoxycholate (AMB; Cristália, Itapira, SP, Brazil), itraconazole (ITZ; Janssen Pharmaceutical), and terbinafine (TRB; Novartis, Basel, Switzerland) and were tested in twofold dilutions at concentrations of 0.0625-32 μg/ml for ITZ and AMB and 0.0078-4 μg/ml for TRB. 
Preparation of inocula
The inoculum of the filamentous phase was obtained from young colonies on PDA agar incubated at 30
• C for 7 days.
Sterile saline (1 ml) was added to each colony, and then the fungal suspension was scraped with a sterile tip. The suspension was placed in a sterile tube, and after 10 minutes, the time required for sedimentation, the supernatant was transferred to another sterile tube and homogenized by vortexing for 15 seconds. The density of the suspension was determined by spectrophotometry and adjusted to optical densities (OD) of 0.09-0.13 using a 530-nm filter. Then, this solution was diluted in RPMI 1640 medium (1:50) with MOPS buffer, corresponding to 2× the concentration required for the test (0.4 × 10 4 to 5 × 10 4 CFU/ml), according to the M38-A2 protocol of the Clinical and Laboratory Standards Institute (CLSI). The yeast fungal inoculum was obtained from young colonies of S. brasiliensis grown on BHI agar at 35
• C for approximately 7 days following two passages. The fungal suspension was produced as described above for the filamentous phase, and adjusted with sterile saline to the same transmittance by spectrophotometry of the standard 0.5 McFarland scale with a 530-nm filter, yielding a final concentration of 1 × 10 6 to 5 × 10 6 CFU/ml. This suspension was then diluted 1:100 in sterile saline and subsequently 1:20 in RPMI with MOPS buffer, resulting in a concentration of 5 × 10 2 to 2.5 × 10 3 CFU/ml according to the M27-A3 protocol of CLSI. Both the yeast and filamentous inocula were produced in sufficient quantity to fill each microplate well with 0.1 ml of suspension. In all tests, the pour-plate method was used to confirm the inoculum concentration. 20 
Antifungal activity
The microdilution technique was performed in accordance with the protocol M38-A2 (CLSI) for the filamentous phase of S. brasiliensis. 12 For the yeast phase, the protocol M27-A3 (CLSI) was used 21 but with an incubation period of 5 days instead of 1-2 days, as described previously. 15, 22, 23 The RPMI 1640 medium buffered with 165 mM of morpholinepropanesulfonic acid (MOPS) was used to perform the technique. Results were evaluated visually, and the minimum inhibitory concentration (MIC), that is, the lowest antifungal concentration that inhibited 80% (for TRB) or 100% (for AMB and ITZ) of fungal growth compared to the positive control, was determined. The minimal fungicidal concentration (MFC) was defined as the lowest antifungal concentration which killed the fungal cells. 21 To determine the MFC, a 10-μL aliquot from each well of the MIC test, with concentrations equal to and greater than the MIC, was plated in Sabouraud agar in duplicate and incubated at 30
• C for 7 days. 19 Tests were performed in duplicate for each fungal isolate.
Statistical analysis
A descriptive analysis was performed using geometric mean (GM) values. Comparisons between results from the yeast and filamentous phases and between results of the antifungal agents tested were evaluated by Wilcoxon test using SPSS 20.0. Statistical significance was considered at a level of 95%. For each antifungal tested, the MIC50 and MIC90 (i.e., the lowest antifungal concentrations able to inhibit 50% and 90%, respectively, of the fungal growth of the isolates), as well as the MFC50 and MFC90 (i.e., the lowest concentrations able to kill the 50% and 90%, respectively, of the fungi isolates) were calculated.
Results
The most active antifungal in vitro against both the filamentous phase and yeast phase of the 35 isolates of S. brasiliensis in our study was TRB, showing a GM of the MIC of 0.343 μg/ml and 0.127 μg/ml, respectively. In the yeast phase, the GM of the MIC was significantly lower than that of both ITZ (P = .009) and AMB (P < .001). However, in the filamentous phase, the GM of the MIC was significantly lower than that of AMB (P < .001) but not different from that of ITZ (P = .091) ( Table 2) . AMB was the antifungal with the highest GM of the MIC for both phases of S. brasiliensis tested (1.486 μg/ml for the filamentous phase and 0.660 μg/ml for the yeast).
In the filamentous phase, more than 50% of the isolates showed MIC values between only two of the concentrations tested, ranging from 0.25 to 0.50 μg/ml for TRB (18/35) (Fig. 2 ). These differences in MICs, with higher values for the filamentous phase than the yeast phase, were significant for TRB (P = .025) and AMB (P = .001) but not for ITZ (P = .933).
High MIC values (≥4 μg/ml) of ITZ and AMB, as described in document M38-A2, were found in 20% (7/35) and 17.1% (6/35), respectively, of the isolates in the filamentous phase, and in 14.2% (5/35) and 5.7% (2/35), respectively, in the yeast phase (Fig. 2) .
With regards to fungicidal activity of the three antifungals tested, the GM of the MFC and the MFC50 values were also lower in the yeast than in the filamentous phase of S. brasiliensis isolates tested (Table 3 
Discussion
Although several prior studies have demonstrated differences in the in vitro antifungal activity between filamentous and yeast phases of Sporothrix spp., 13, 14, 15, 22 many of these studies occurred prior to 2007, when the clinical isolates of sporotrichosis were all identified as S. schenckii. 13, 14, 22 Studies on the in vitro antifungal susceptibilities of different species in the complex Sporothrix, especially for S. brasiliensis, a species with zoonotic transmission and high virulence, are still scarce, 10, 23 with few data available in the literature. 7, 15, 18, 19 In this context, our study contributes to increase the data on the susceptibility of both phases, testing 35 isolates of S. brasiliensis obtained from an outbreak of feline sporotrichosis in southern Rio Grande do Sul, Brazil, an area with high incidence of the disease. 8, 9 TRB was the most effective antifungal with in vitro activity showing the lowest MIC values, which supports findings from other studies that tested S. brasiliensis isolates. 11, 15, 19 However, in our study, the GM of the MICs of TRB for the filamentous phase were three to six times higher than those described in other reports, 7, 15, 19 with an MIC > 0.50 in 20% of the isolates. TRB was shown to have high activity against S. brasiliensis. However, the therapeutic potential of TRB has been confirmed only for cutaneous and lymphocutaneous sporotrichosis. 7, 19, [24] [25] [26] Furthermore, this drug is known not to be effective for the treatment of systemic sporotrichosis in a murine model. 7, 19, 27 Although a few reports on the clinical efficacy of TRB exist on systemic sporotrichosis, there is not enough data to recommend its use as a possible alternative treatment. 13, 28 AMB showed the highest GM of the MIC values when comparing to those from ITZ and TRB in our study, corroborating with previously reported data by Marimon et al. (2008) and Stopiglia et al. (2014] ). Primary resistance of Sporothrix spp. to AMB had already been demonstrated, 29 as well as treatment failure associated with low susceptibility of strains in this genus to this antifungal. 30 In the study from Borba-Santos et al. (2015) the ITZ was the antifungal with higher GM of MIC against the S. brasiliensis evaluated. We also found high rates of isolates with high ITZ MIC values (>4 μg/ml), reaching 14.2 and 20% of the isolates in the yeast and filamentous phases, respectively. These high MIC values could possibly be a result of selective pressure that promoted the development of an acquired resistance through mechanisms involving a plasma membrane efflux pump and ATP-binding cassette (ABC) transporters 15 because of the prolonged course of the disease. 8, 11, 16 Several studies reported that different antifungal susceptibility profiles can be found between phases of dimorphic fungi. 15, 31 In our study, significantly higher TRB and AMB MIC values were observed for the filamentous phase in comparison to the yeast phase. Although these data corroborate findings of other studies against Sporothrix spp., 13,31 they differ from those described by Borba-Santos et al. (2015), which is the only other study that performed tests with both phases of S. brasiliensis and with a similar number of isolates as used in our study. Some studies have found little variation in the MIC values between the isolates tested, especially for TRB. 13, 31 This was not the case in our study, with just over half of the isolates showing MIC values in the same ranges (0.25-0.50 μg/ml for the filamentous and 0.125-0.25 μg/ml for the yeast phase).
One explanation for this difference in the susceptibility of S. brasiliensis phases is the concentration of melanin in the cell wall, which is found in greater quantities in the filamentous phase than in the yeast phase, and which is associated not only with virulence but also with an increase in resistance to antifungal drugs. [32] [33] [34] In support to this idea, a study showed that S. brasiliensis cells became more resistant to amphotericin B after melanization in medium with L-dopa or L-tyrosine. 35 Microdilution test for Sporothrix spp. is addressed in the M38-A2 document of CLSI, which describes the steps of an in vitro antifungal test for the filamentous saprophytic phase instead for the yeast pathogenic phase of this fungi. 12 Thus, the lower MIC for the yeast phase, in comparison with those for the filamentous form found in our study as well as described by other authors, 13, 31 reinforces the necessity of standardization a protocol to in vitro antifungal tests of the yeast form of Sporothrix spp. 15 Yet, these laboratorial tests done with the yeast pathogenic form could result in a better correlation between in vitro resistance and in vivo therapeutic failure.
14 Although a breakpoint has not been specifically established for Sporothrix spp., ITZ and/or AMB MIC values of ≥ 4 μg/ml, found in about 5-20% of the isolates tested in this study in both phases, may represent resistance and consequent treatment failure. 12 Similar percentages of isolates showing high MIC values of both ITZ and AMB were described by Borba-Santos et al. (2015) . However, these authors described a number approximately three times higher for AMB than in our study in the yeast phase (18.75% vs 5.7%). Considering the role of melanin as an interfering factor in antifungal activity in vitro, this difference could be explained by our use of RPMI medium without glucose for the yeast phase, as this substrate was added in the modified technique by Borba-Santos et al. Unlike other studies that include isolates from different countries, states, or regions, all of the clinical isolates evaluated in this study were from a single outbreak of feline sporotrichosis that occurred between 2010 and 2014, with samples coming from southern Rio Grande do Sul, Brazil. This kind of regional studies are important since strains from one location could differ genetically from those of other locations. In fact, the difference between the strains of S. brasiliensis from Rio Grande do Sul and those from São Paulo, Minas Gerais, and Paraná, Brazil, was described, with these last three locations sharing the same genotype from the outbreak of zoonotic sporotrichosis in Rio de Janeiro. 35, 36 Moreover, considering that differences in antifungal susceptibility can occur due to intrinsic factors of the isolates, these data highlight the importance of understanding the epidemiology and resistance profiles of local isolates for appropriate therapies and better control of disease dissemination.
